Somatic mutation of the cohesin complex subunit confers therapeutic vulnerabilities in cancer
JournalJournal of Clinical Investigation
PublisherAmerican Society for Clinical Investigation
MetadataShow full item record
AbstractA synthetic lethality-based strategy has been developed to identify therapeutic targets in cancer harboring tumor-suppressor gene mutations, as exemplified by the effectiveness of poly ADP-ribose polymerase (PARP) inhibitors in BRCA1/2-mutated tumors. However, many synthetic lethal interactors are less reliable due to the fact that such genes usually do not perform fundamental or indispensable functions in the cell. Here, we developed an approach to identifying the "essential lethality" arising from these mutated/deleted essential genes, which are largely tolerated in cancer cells due to genetic redundancy. We uncovered the cohesion subunit SA1 as a putative synthetic-essential target in cancers carrying inactivating mutations of its paralog, SA2. In SA2-deficient Ewing sarcoma and bladder cancer, further depletion of SA1 profoundly and specifically suppressed cancer cell proliferation, survival, and tumorigenic potential. Mechanistically, inhibition of SA1 in the SA2-mutated cells led to premature chromatid separation, dramatic extension of mitotic duration, and consequently, lethal failure of cell division. More importantly, depletion of SA1 rendered those SA2-mutated cells more susceptible to DNA damage, especially double-strand breaks (DSBs), due to reduced functionality of DNA repair. Furthermore, inhibition of SA1 sensitized the SA2-deficient cancer cells to PARP inhibitors in vitro and in vivo, providing a potential therapeutic strategy for patients with SA2-deficient tumors. Copyright 2018 American Society for Clinical Investigation. All rights reserved.
SponsorsThis work was funded in part by US NIH grants R01CA203737 (to XL) and R01CA206366 (to XH and XL), the Vera Bradley Foundation (to XL), National Natural Science Foundation of China grant 81620108030 (to GJ), and the Indiana University Strategic Research Initiative fund (to XL).
Identifier to cite or link to this itemhttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85049834063&doi=10.1172%2fJCI98727&partnerID=40&md5=d52d2ed86e78a935cea7de71195c5218; http://hdl.handle.net/10713/9686
- A requirement for STAG2 in replication fork progression creates a targetable synthetic lethality in cohesin-mutant cancers.
- Authors: Mondal G, Stevers M, Goode B, Ashworth A, Solomon DA
- Issue date: 2019 Apr 11
- Distinct functions of human cohesin-SA1 and cohesin-SA2 in double-strand break repair.
- Authors: Kong X, Ball AR Jr, Pham HX, Zeng W, Chen HY, Schmiesing JA, Kim JS, Berns M, Yokomori K
- Issue date: 2014 Feb
- Characterization of the interaction between the cohesin subunits Rad21 and SA1/2.
- Authors: Zhang N, Jiang Y, Mao Q, Demeler B, Tao YJ, Pati D
- Issue date: 2013
- Cohesin mutations alter DNA damage repair and chromatin structure and create therapeutic vulnerabilities in MDS/AML.
- Authors: Tothova Z, Valton AL, Gorelov RA, Vallurupalli M, Krill-Burger JM, Holmes A, Landers CC, Haydu JE, Malolepsza E, Hartigan C, Donahue M, Popova KD, Koochaki S, Venev SV, Rivera J, Chen E, Lage K, Schenone M, D'Andrea AD, Carr SA, Morgan EA, Dekker J, Ebert BL
- Issue date: 2021 Feb 8
- Differential regulation of telomere and centromere cohesion by the Scc3 homologues SA1 and SA2, respectively, in human cells.
- Authors: Canudas S, Smith S
- Issue date: 2009 Oct 19